- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Di | Novo Nordisk's weight loss pill approved by FDA | ||
| Di | Biopharma CEO optimism is wavering in the US | ||
| Mo | Biopharma climbs higher as 9 drugmakers ink 'pandering' drug price deals with Trump | ||
| Mo | Radiopharmaceutical specialist Aktis seeks an IPO | ||
| Mo | Cytokinetics set to battle Bristol Myers as FDA approves heart drug | ||
| 19.12. | Patient deaths put Merck, Daiichi's ADC trial on partial hold | ||
| 19.12. | Galapagos TYK2 drug hits goal in one trial, misses in another | ||
| 19.12. | BioMarin to buy rare disease drugmaker Amicus for $4.8B | ||
| 19.12. | Novo files for CagriSema approval; Merck and Pfizer's trial win | ||
| 18.12. | Moderna gets funding for H5 pandemic influenza vaccine | ||
| 18.12. | Lilly obesity pill, headed for quick FDA review, hits mark in 'maintenance' trial | ||
| 18.12. | Insmed's 'win streak' ends as top drug fails study in chronic nasal condition | ||
| 18.12. | Takeda says $4B TYK2 drug succeeds in large psoriasis studies | ||
| 18.12. | Orum, a biotech marrying ADCs with protein degraders, captures $100M in funding | ||
| 17.12. | FDA clears GSK's twice-yearly asthma drug | ||
| 17.12. | Peanut allergy patch succeeds in late-stage study 5 years after FDA rejection | ||
| 17.12. | RA Capital backs drug for rare kind of chronic pain | ||
| 17.12. | Addition emerges with $100M to make gene therapies for chronic and rare diseases | ||
| 16.12. | Developing a path forward in cancer cachexia | ||
| 16.12. | Nektar sees silver lining as autoimmune drug 'narrowly' misses in alopecia study | ||
| 16.12. | FDA 'proactively' hands J&J a voucher; Pfizer issues 2026 forecasts | ||
| 16.12. | Enhertu combo cleared for use in frontline breast cancer | ||
| 16.12. | 'Zombie' biotech buyer Xoma to acquire Generation Bio | ||
| 15.12. | Argenx falters in effort to expand immune drug's use | ||
| 15.12. | Sanofi MS drug hits two setbacks |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .